Hematology Practice Questions

Q: Which of the following is NOT a feature of POEMS Syndrome?

Multiple sclerosis. ***Multiple sclerosis*** - **Multiple sclerosis** is a chronic, demyelinating disease of the central nervous system and is not part of the diagnostic criteria or typical manifestations of POEMS syndrome [1]. - POEMS syndrome is a **paraneoplastic syndrome** associated with plasma cell dyscrasia, not an autoimmune CNS disorder [2]. *Polyneuropathy* - **Polyneuropathy** is a core and defining feature of POEMS syndrome, typically a demyelinating sensorimotor type [2]. - The "P" in POEMS stands for **Polyneuropathy**. *Organomegaly* - **Organomegaly**, particularly hepatomegaly, splenomegaly, or lymphadenopathy, is a common feature of POEMS syndrome. - The "O" in POEMS stands for **Organomegaly**. *Endocrinopathy* - **Endocrinopathy**, such as hypogonadism, diabetes mellitus, or hypothyroidism, is frequently observed in POEMS syndrome [2]. - The "E" in POEMS stands for **Endocrinopathy**.

Q: Deep vein thrombosis most commonly occurs at which site?

Femoral vein. ***Femoral vein*** - The **femoral vein**, along with the **popliteal** and **iliac veins**, are the most common sites for **deep vein thrombosis (DVT)** in the lower extremities [1]. - Due to their size and the dynamics of blood flow in these regions, they are prone to clot formation, especially in the presence of **Virchow's triad**. *Subclavian vein* - While DVT can occur in the subclavian vein (an **upper extremity DVT**), it is less common than in the lower extremities [1]. - Upper extremity DVTs are often associated with **central venous catheters** or **thoracic outlet syndrome**. *External jugular vein* - **External jugular vein thrombosis** is rare and usually associated with local trauma, infection, or central line placement, not typically primary DVT [1]. - It is a superficial vein and not considered a common site for typical deep vein thrombosis. *Internal jugular vein* - **Internal jugular vein thrombosis** is also uncommon as a primary DVT and often secondary to neck infections, malignancies, or indwelling catheters [1]. - Like the subclavian vein, it's considered an upper extremity DVT site, but less frequent than lower extremity sites.

Q: Which of the following does not synthesize von Willebrand factor?

Hepatocytes. ***Hepatocytes*** - Von Willebrand factor (vWF) is primarily synthesized by **endothelial cells** and **megakaryocytes** [1], not hepatocytes. - Hepatocytes are responsible for synthesizing other proteins like **clotting factors**, but not vWF. *Megakaryoctyes* - Megakaryocytes play a crucial role in the synthesis of **platelet-derived factors**, including von Willebrand factor (vWF) [1]. - They release vWF into the bloodstream, facilitating platelet adhesion, especially in vascular injury sites. *None* - The option implies all listed cell types synthesize vWF, which is incorrect, as **only endothelial cells and megakaryocytes** produce it [1]. - Suggests a misunderstanding of the synthesis of coagulation-related factors, as hepatocytes do not produce vWF. *Endothelial cells* - Endothelial cells are the primary source of **von Willebrand factor** [1], releasing it to assist in platelet aggregation and clotting. - They are essential for the body's response to vascular injury, facilitating hemostasis. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 669-670.

Q: Response to iron therapy in iron deficiency anemia is denoted by?

Reticulocytosis. Reticulocytosis - Reticulocytosis is one of the earliest signs of a positive response to iron therapy in iron deficiency anemia, occurring within 5-10 days. - It signifies that the bone marrow is effectively producing new red blood cells after iron supplementation. Restoration of enzymes - While iron is a crucial component of many enzymes (e.g., catalase, cytochrome oxidase), its restoration takes time and is not the primary immediate indicator of therapeutic response. - Clinical improvement and other hematological parameters precede the full restoration of enzyme function. Increase in hemoglobin - An increase in hemoglobin is a definitive sign of successful treatment, but it occurs later than reticulocytosis, typically visible after several weeks to months of therapy. - Hemoglobin levels rise as the new, iron-sufficient red blood cells fully mature and replace the older, iron-deficient ones. Increase in iron binding capacity - In iron deficiency anemia, total iron-binding capacity (TIBC) is typically increased due to more transferrin being available to bind iron [1]. - Successful iron therapy would lead to a decrease in TIBC as transferrin sites become saturated with iron, not an increase.

Q: Cryoprecipitate is useful in which of the following conditions?

Afibrinogenemia. ***Afibrinogenemia*** - Cryoprecipitate is rich in **fibrinogen**, factor VIII, factor XIII, von Willebrand factor, and fibronectin. It is the only blood product with a substantial concentration of fibrinogen. - **Afibrinogenemia** (or hypofibrinogenemia) is a condition characterized by low or absent levels of fibrinogen, a critical clotting factor that cryoprecipitate replaces effectively. *Hemophilia A* - Hemophilia A is a deficiency of **Factor VIII**. While cryoprecipitate contains factor VIII, **recombinant Factor VIII concentrates** are the preferred treatment due to better safety (reduced risk of viral transmission) and more precise dosing [1]. - Cryoprecipitate was historically used for Hemophilia A before the availability of safer, more specific factor concentrates [2]. *Thrombosthenia* - Thrombasthenia is a platelet function disorder characterized by defective **glycoprotein IIb/IIIa receptors** on platelets, leading to impaired platelet aggregation. - Cryoprecipitate does not contain platelets or factors that directly correct platelet function, making **platelet transfusions** the treatment of choice for severe bleeding in thrombasthenia. *Warfarin reversal* - Warfarin reversal is primarily achieved using **Vitamin K**, which restores levels of functional clotting factors II, VII, IX, and X. - For rapid reversal in emergencies, **prothrombin complex concentrate (PCC)** is preferred because it contains high concentrations of these vitamin K-dependent factors, addressing the primary deficiency caused by warfarin [1].

Q: Which of the following statements about Sickle Cell Anemia is FALSE?

Patients usually present before the age of 6 months. ***Patients usually present before the age of 6 months*** - This statement is **FALSE** because sickle cell anemia patients typically become symptomatic **after 6 months of age**, when **fetal hemoglobin (HbF)** levels decline. - **HbF is protective** against sickling, so symptoms like **dactylitis** and **splenic sequestration** usually manifest once HbF is replaced by HbS. *There is a positive correlation between HBS and polymerization of HBS* - This statement is **TRUE** as higher levels of **hemoglobin S (HbS)** lead to increased **polymerization** and sickling of red blood cells. - The **polymerization of deoxygenated HbS** is the primary pathophysiologic mechanism causing vaso-occlusive crises and hemolysis. *Recurrent infections is the most common cause of death* - This statement is **TRUE**, particularly in children with sickle cell anemia due to **functional asplenia** from repeated splenic infarctions. - **Splenic dysfunction** impairs clearance of **encapsulated bacteria**, increasing risk of severe infections like **pneumococcal sepsis** and **meningitis**. *Patients require frequent blood transfusions* - This statement is **TRUE** as **chronic transfusion therapy** is a standard treatment for managing severe complications and preventing stroke. - Transfusions help **suppress HbS production**, dilute existing sickle cells, and reduce the frequency of **vaso-occlusive crises**.

Q: In which anatomical location are spontaneous bleeding manifestations most commonly first observed in patients with bleeding disorders?

Oral mucosa. ***Oral mucosa*** - The **oral mucosa** (including gums, buccal mucosa, and tongue) is the **most common site** for first spontaneous bleeding manifestations in patients with bleeding disorders [1]. - **Gingival bleeding** and **oral petechiae/ecchymoses** are hallmark early signs of **thrombocytopenia** and **platelet function disorders**. - The oral cavity's highly vascular mucous membranes and constant minor trauma from mastication make it particularly susceptible to spontaneous bleeding [1]. - **Epistaxis** (nosebleeds) is another very common early mucosal bleeding site, often presenting alongside oral bleeding [1]. *Conjunctiva* - While **subconjunctival hemorrhage** can occur in bleeding disorders, it is **not typically the first or most common site** of spontaneous bleeding. - Conjunctival bleeding is more often associated with local trauma, valsalva maneuvers, or severe thrombocytopenia rather than being an initial presentation. - When present, it usually accompanies other mucocutaneous bleeding manifestations. *Abdomen* - Intra-abdominal bleeding is a **serious complication** that occurs in severe or advanced bleeding disorders, not as an initial manifestation [1]. - It presents with pain, distension, and signs of hypovolemic shock rather than as a subtle, early visible sign. - This typically indicates deep tissue bleeding seen in **coagulation factor deficiencies** (hemophilia) rather than platelet disorders. *Scalp* - Scalp bleeding is uncommon as a spontaneous first manifestation in bleeding disorders. - **Cephalohematoma** or **subgaleal hemorrhage** in newborns is usually birth trauma-related. - Spontaneous scalp hemorrhage would suggest severe coagulopathy and is not a typical early presentation.

Q: Which of the following statements is true regarding pernicious anemia?

Increased red cell MCV. ***Increased risk of gastric carcinoma is unlikely*** - **Pernicious anemia** significantly increases the risk of **gastric carcinoma** due to the chronic inflammation from atrophic gastritis. - This association is well-documented and highlights the **precancerous potential** of the condition. *Increased red cell MCV* - In pernicious anemia, there is often a **macrocytic anemia** characterized by an **increased mean corpuscular volume (MCV)**. - This occurs due to impaired DNA synthesis caused by vitamin B12 deficiency [2]. *Elevated serum levels of methyl malonic acid* - Patients with pernicious anemia will have **elevated levels of methylmalonic acid** due to decreased vitamin B12, impacting the metabolism of certain fatty acids. - This biochemical marker helps in differentiating deficiency of vitamin B12 from other forms of anemia. *Chronic atrophic gastritis* - Chronic atrophic gastritis is a **common feature** in pernicious anemia, leading to gastric mucosal atrophy and impaired intrinsic factor production [1]. - This condition is directly related to the **autoimmune nature** of pernicious anemia, further compromising vitamin B12 absorption [1].

Question 1

Which of the following is NOT a feature of POEMS Syndrome?

Accepted Answer

Multiple sclerosis

Answer

Organomegaly

Answer

Endocrinopathy

Answer

Polyneuropathy

Question 2

Deep vein thrombosis most commonly occurs at which site?

Accepted Answer

Femoral vein

Answer

Subclavian vein

Answer

External jugular vein

Answer

Internal jugular vein

Question 3

Which of the following does not synthesize von Willebrand factor?

Accepted Answer

Hepatocytes

Answer

Endothelial cells

Answer

Megakaryocytes

Answer

None of the options

Question 4

Response to iron therapy in iron deficiency anemia is denoted by?

Accepted Answer

Reticulocytosis

Answer

Increase in hemoglobin

Answer

Restoration of enzymes

Answer

Increase in iron binding capacity

Question 5

Cryoprecipitate is useful in which of the following conditions?

Accepted Answer

Afibrinogenemia

Answer

Hemophilia A

Answer

Thrombosthenia

Answer

Warfarin reversal

Question 6

Thrombotic thrombocytopenic purpura is a syndrome characterized by which of the following?

Accepted Answer

Thrombocytopenia, anemia, neurological abnormalities, progressive renal failure and fever

Answer

Thrombocytopenia, anemia, neurological abnormalities, progressive hepatic failure and fever

Answer

Thrombocytopenia, normal anemia, neurological abnormalities, progressive renal failure and fever

Answer

Thrombocytopenia, anemia, no neurological abnormalities, progressive renal failure and fever

Question 7

Which of the following statements about Sickle Cell Anemia is FALSE?

Accepted Answer

Patients usually present before the age of 6 months

Answer

There is a positive correlation between HBS and polymerization of HBS

Answer

Recurrent infections is the most common cause of death

Answer

Patients require frequent blood transfusions

Question 8

In which anatomical location are spontaneous bleeding manifestations most commonly first observed in patients with bleeding disorders?

Accepted Answer

Oral mucosa

Answer

Abdomen

Answer

Conjunctiva

Answer

Scalp

Question 9

Which of the following statements regarding iron supplementation in iron deficiency anemia is incorrect?

Accepted Answer

If gastric intolerance to oral iron therapy occurs, all patients should be administered parenteral forms

Answer

Administer a small diluted dose first prior to infusion to look for any allergy to iron preparation

Answer

Parenteral iron supplementation is required in a patient with Hb of less than 7 mg/dL

Answer

Oral iron therapy should be stopped once the patient achieves a hemoglobin of >12 mg/dL

Question 10

Which of the following statements is true regarding pernicious anemia?

Accepted Answer

Increased red cell MCV

Answer

Chronic atrophic gastritis

Answer

Elevated serum levels of methyl malonic acid

Answer

Increased risk of gastric carcinoma

Hematology — MCQs

Hematology — MCQs

On this page

Practice by Chapter

Want unlimited practice?